Attovia Therapeutics
6 known investors
Attovia develops precision biologics using its ATTOBODY platform for patients with immune-mediated diseases. The company creates novel complex biologic medicines through modular protein design.
Investors · 6
In the news
- Attovia Therapeutics Files for US IPO to Advance Pipeline of Immune Disease Therapiesmedicaldialogues.in · 2026
- Goldman Sachs-backed biopharma company Attovia Therapeutics files for US IPOpharma.economictimes.indiatimes.com · 2026
- Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno - BioSpacebiospace.com · 2026
- Braveheart, Attovia join next wave of biotech IPOs | BioPharma Divebiopharmadive.com · 2026
- Attovia files for IPO to take on Sanofi and Regeneron’s Dupixentfiercebiotech.com · 2026
- Attovia Therapeutics files for IPO on Nasdaq By Investing.cominvesting.com · 2026